Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Emergent BioSolutions Inc. Director's Dealing 2012

Mar 12, 2012

32870_dirs_2012-03-12_af3b3f6a-8e79-491a-971b-29f181a212d2.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2012-03-08

Reporting Person: El-Hibri Fuad (Director, CEO & Chairman, 10% Owner)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2012-03-08 Common Stock F 3730 $14.49 Disposed 1501868 Direct

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 15769 Indirect
Common Stock 15769 Indirect
Common Stock 15769 Indirect
Common Stock 5636794 Indirect
Common Stock 1524155 Indirect
Common Stock 1565043 Indirect

Footnotes

F1: Mr. El-Hibri's direct holdings include restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.

F2: These shares are held in a trust for the benefit of a child of the reporting person. The reporting person is trustee of this trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

F3: Mr. El-Hibri holds with his wife, as tenants by the entirety, an aggregate 41.1072% equity interest in Intervac, L.L.C. After the distribution by Intervac, L.L.C. to Mr. El-Hibri and other members of Intervac, L.L.C. of 500,000 shares of Common Stock, Intervac, L.L.C. is the direct owner of 5,636,794 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 2,317,129 shares.

F4: Mr. El-Hibri holds individually and with his wife, as tenants by the entirety, an aggregate 89.2% equity interest in Biovac, L.L.C. Biovac, L.L.C. is the direct owner of 1,524,155 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of the shares of Common Stock directly owned by Biovac, L.L.C. for purposes of Section 16, except to the extent of his pecuniary interest in 1,359,546 shares.

F5: Mr. El-Hibri is the holder of a 40.17% (567,582.3 units) equity interest in BioPharm, L.L.C. BioPharm, L.L.C. is the direct owner of 1,565,043 shares of Common Stock. Mr. El-Hibri disclaims beneficial ownership of these shares for purposes of Section 16, except to the extent of his pecuniary interest in 628,678 shares.